Delivery Order SPE2DB22D9207-SPE2DB25FH5AB

Award Date 5/12/25
Potential Completion Date 6/3/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 25, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $49,324.08, is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 8, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract provides for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of April 30, 2025 and is not associated with a set-aside designation. DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,795.18 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of November 14, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $98,648.16 contract is for the provision of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of April 8, 2025 and is not associated with any set-aside designations. DMS Pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a prescription medication. The award has a ceiling value of $48,749.85 and a completion date of June 6, 2025. DMS Pharmaceutical Group Inc. is the prime contractor and there are no major subcontractors mentioned. This award is part of a larger Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the provision of STELARA 90 MG/ML SYRINGE/ML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 16, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML pharmaceutical products. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 1, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB25FH5AB
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $24,662.04, is for the delivery of STELARA 90 MG/ML SYRINGEML, a prescription medication. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of pharmaceutical products to federal agencies, including the Department of Defense. The contract has a completion date of June 3, 2025 and is not set aside for any specific type of business. DMS Pharmaceutical Group Inc. also holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $499,999,999, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide.

Generated 8/17/25, 1:18 AM